30.9 C
New York
Sunday, June 14, 2026

Tag: medication

newssourceFORcompanyinformationcontent1marketreleases

Comphya Closes Oversubscribed CHF 7.5 Million Series A Round to Advance U.S. and Australian Clinical Programs Following Strong Pilot Data

- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins
- Series B round in planning to support pivotal U.S. trial
- New CEO appointment signals next phase of growth and expansion

CathVision Announces New Software Release and New Board Appointment

COPENHAGEN, Denmark, July 7, 2025 /PRNewswire/ -- CathVision ApS, a medical technology company developing electrophysiology solutions for cardiac ablation, announces the market release of...

Public Advisory – NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug

OTTAWA, ON, July 5, 2025 /CNW/ - Summary Product: NRA-Amlodipine 5 mg, DIN 02476460Issue: Health products - Product safetyWhat to do: Check your bottle of NRA-Amlodipine 5 mg...

Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm’s Series of...

SHENZHEN, China, July 4, 2025 /PRNewswire/ -- Recently, Kexing Biopharm made a remarkable appearance at CPHI & PMEC China 2025 and successfully organized the...

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management. 
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

Neuro Balance Therapy Update: Strongest Non-Clinical Reflex Routine for Seniors Concerned About Instability

New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+ 
New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+

NECC Selects MedMinder to Transform Their Medication Management for Individuals with Autism They Serve

NORWOOD, Mass., July 3, 2025 /PRNewswire/ -- The New England Center for Children (NECC), a globally recognized leader in autism education and research, has contracted...

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson’s Disease and identifies clear opportunities...

ALTRINCHAM, England, July 3, 2025 /PRNewswire/ -- A new study is the first to examine the application of behavioural science in getting underused therapies...

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson’s Disease and identifies clear opportunities...

ALTRINCHAM, England, July 3, 2025 /PRNewswire/ -- A new study is the first to examine the application of behavioural science in getting underused therapies...

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

GlucoTru Pro Releases 2025 Health Integrity Update on Blood Pressure & Blood Sugar Balance Innovation

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions. 
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

Direct Meds Launches Company-Wide AI Program to Scale Patient Care Amid Explosive Growth

Direct Meds LLC, a fast-scaling telemedicine provider serving the US and Canada, today announced a company-wide deployment of artificial intelligence (AI).

TRC Healthcare Launches Upgraded NatMed Pro to Further Support Evidence-Based Natural Medicine Use with Smarter Tools

DENVER, July 1, 2025 /PRNewswire/ -- TRC Healthcare, the leading provider of evidence-based medication-related resources, announced last week the launch of an upgraded NatMed...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedication

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers